AngioDynamics, Inc. filings document regulatory disclosures for a Nasdaq-listed medical technology company focused on vascular disease, thrombectomy, oncology and surgical device markets. Recent Form 8-K reports furnish quarterly and annual financial results, Regulation FD investor presentation materials, and forward-looking statement language tied to product strategy, competitive position, cash flows and operating plans.
The filing record also covers governance and material-event disclosures, including annual meeting voting results, director elections, auditor ratification, advisory executive-compensation votes, executive transition and retirement arrangements, and patent-enforcement litigation involving the company’s thrombectomy intellectual property and self-expanding funnel technology. Proxy materials provide compensation tables, board matters and shareholder-vote mechanics.
AngioDynamics Inc EVP and CFO Stephen A. Trowbridge reported equity award activity related to performance share units granted on July 19, 2023. Based on performance metrics and relative total shareholder return, 16,296 shares of Common Stock vested and were issued from a 57,381-unit target grant, with the remaining units forfeited. To satisfy related tax withholding obligations, 8,319 shares were withheld at $13.82 per share.
AngioDynamics Inc. President and CEO James C. Clemmer reported the vesting and settlement of a performance share grant on July 22, 2026. A 2023 target grant of 184,361 performance share units was settled based on multi-year performance, resulting in issuance of 52,358 shares of Common Stock and forfeiture of the remaining units. Of the issued shares, 26,728 were disposed of at $13.8200 per share to satisfy tax withholding obligations, with the balance retained as directly owned common stock.
Chad Thomas Campbell, SVP/GM Vascular Access at AngioDynamics, reported the vesting of 6,466 shares of Common Stock on July 22, 2026, from performance share units granted July 19, 2023. A target of 22,768 performance share units could pay out 0–200%, with an additional 20% adjustment tied to relative total shareholder return over fiscal years 2024–2026; unearned units were forfeited. To cover tax withholding on the vesting, 2,330 shares were disposed at $13.82 per share.
REED JAN STERN reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc. director Jan Stern Reed received a grant of 11,887 shares of common stock on July 15, 2026, reported at a price of $0.00 per share. A footnote explains this represents 11,887 restricted stock units granted as regular annual compensation for board service that immediately vested at grant. Following this award, Reed directly holds 116,921 common shares.
Licitra Karen A reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc. director Karen A. Licitra received a grant of 11,887 shares of common stock on July 15, 2026, representing 11,887 restricted stock units as regular annual compensation for board service. These units immediately vested at grant, increasing her direct holdings to 102,322 shares.
JOHNSON WESLEY reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc. director Wesley Johnson received a grant of 11,887 shares of common stock in the form of restricted stock units on 2026-07-15 as regular annual compensation for board service. The units immediately vested, bringing his directly held common shares to 155,425.
DONNELLY HOWARD W reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics Inc director Howard W. Donnelly received a grant of 11,887 shares of common stock on July 15, 2026, representing 11,887 restricted stock units granted as regular annual compensation for board service. These units vested immediately, increasing his directly held common stock to 178,938 shares.
Burgess Lorinda reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics director Lorinda Burgess received an equity award of 11,887 restricted stock units as regular annual compensation for board service on July 15, 2026. These RSUs immediately vested at grant, increasing her directly held common stock to 67,144 shares. The award was a no-cost stock grant and was not made under a Rule 10b5-1 trading plan.
AngioDynamics Inc director Auen Eileen O'Shea reported the acquisition of 11,887 shares of common stock, representing 11,887 restricted stock units granted as regular annual compensation for board service. These units vested immediately at grant, bringing her direct holdings to 116,605 shares of AngioDynamics common stock.
Tarnoff Michael E reported acquisition or exercise transactions in this Form 4 filing.
AngioDynamics director Michael E. Tarnoff received a grant of 11,887 shares of common stock on July 15, 2026, representing restricted stock units granted as regular annual director compensation that immediately vested at grant. After this award, he directly holds 95,265 common shares, and the transaction was not made under a Rule 10b5-1 trading plan.